Please ensure Javascript is enabled for purposes of website accessibility

Why Madrigal Pharmaceuticals Stock Is On Fire Today

By George Budwell - Dec 6, 2017 at 1:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Madrigal's experimental NASH drug is starting to look like the real deal.

What happened

Shares of Madrigal Pharmaceuticals (MDGL 2.81%) are rocketing higher today after the company announced positive mid-stage results for its experimental non-alcoholic steatohepatitis (NASH) drug, MGL-3196. Turning to the specifics, Madrigal said that patients treated with MGL-3196 experienced a significant decline in the amount of fat in the liver, assessed by magnetic resonance imaging, compared to those receiving a placebo.

As of 1:21 p.m. EST, the drugmaker's shares are up by a healthy 75% on over 20 times the average daily volume in the wake of this encouraging clinical outcome.  

An excited man yelling at his laptop.

Image Source: Getty Images.

So what

NASH is forecast to become of one of the most valuable drug markets over the next decade. This deadly liver disease, after all, presently lacks any form of pharmaceutical intervention approved by the Food and Drug Administration, and its incidence rate is only expected to grow in lockstep with the out-of-control obesity epidemic. In other words, Madrigal may have a potential blockbuster drug on its hands with MGL-3196. 

No what

The downside risk for investors, though, is that numerous companies are racing to bring a NASH drug to market right now. Put simply, there's no way to know which company will ultimately grab the lion's share of this emerging, high-value market. Madrigal, for its part, is well behind the leaders in this heated contest, and it also lacks the formidable resources of some of the top dogs in the NASH race like Allergan and Gilead Sciences.

Bottom like: While this clinical update is encouraging, the most likely near-term outcome will be a sizable secondary offering designed to shore up Madrigal's balance sheet. Investors may therefore want to hold off on buying this shooting star today to wait for a more attractive entry point.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Madrigal Pharmaceuticals, Inc. Stock Quote
Madrigal Pharmaceuticals, Inc.
MDGL
$73.59 (2.81%) $2.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.